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Abstract
Background: Regenerative wound repair is a goal of modern medicine. This is important not only
for the local repair but also for its beneficial effect to systemic physiological processes. When
wounds become chronic, individuals are susceptible to generalized inflammatory cascades that can
affect many organs and even lead to death. Skin is the most commonly injured tissue, and its proper
repair is important for reestablishment of its barrier function.
Results: We show here that insulin, when topically applied to skin excision wounds, accelerates
re-epithelialization and stimulates "maturation" of the healing tissue. These effects are dependent
on the insulin receptor but independent of EGF/EGF-R; PI3K-Akt-Rac1 signaling pathways are
critically involved, and healing is α3 and LN332-dependent.
Conclusion: Insulin has great potential for the treatments of chronic wounds in which re-
epthelialization is impaired. Understanding of the pathways induced by insulin is important for the
development of analog molecules that function strictly in healing. Because of its long history of safe
use in humans for decades, this protein may prove to be a powerful therapy without major adverse
effects.
Background
Wound healing is a complex process that involves sequen-
tial phases that overlap in time and space, interact, and
affect each other dynamically both at the gene and protein
levels. In addition, crosstalk between cells and the sur-
rounding microenvironment contributes to the processes
of clot formation, inflammation, granulation tissue devel-
opment, and remodeling. Many different lines of experi-
mental evidence have shown that the basic cellular and
molecular mechanisms that result in these events involve
cell adhesion/de-adhesion, migration, proliferation, dif-
ferentiation, and apoptosis. One important process initi-
ated during the early stages of healing is re-
epithelialization; it involves the proliferation, migration,
and differentiation of keratinocytes from the wound mar-
gins [1,2]. Appropriate re-epithelialization requires not
only the development of a continuous epidermal layer
but also full epidermal differentiation and the formation
of junctions between the epidermis and dermis. Because
the epidermis provides a barrier against infection and
maintains homeostasis, improving re-epithelialization,
particularly in impaired healing situations, has attracted a
great deal of attention. One molecule with the potential to
enhance these processes is insulin, a hormone known to
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types. It can affect the proliferation, migration [3], and
ECM secretion by keratinocytes, endothelial cells, and
fibroblasts [4].
The use of insulin for non-diabetic purposes was popular
in the early part of the 20th century [5,6], was "forgotten"
during the 40's and 50's, and it became again reinvigor-
ated during the latter half of the century. For example,
daily injections of insulin were used to improve bone
healing in rats [7,8], incision wounds of the skin [9,10],
healing in the distal limb of horses [11], and in cutaneous
ulcerations in diabetic and non-diabetic mice [12]. Insu-
lin was also used in the 60's to treat diabetic wounds in
humans [13,14], and more recently, insulin spray has
been successfully used to treat patients with diabetic
ulcers. Furthermore, this hormone has been used to treat
burns in humans [15], rats [16], and rabbits [17] with
good success. In addition to the studies in vivo, experi-
ments with cultured cells have shown that insulin
increases the rate of growth of fibroblasts, cells that are
critically involved in the development of the granulation
tissue [18], suggesting that insulin can function as a
growth hormone [19]. Nevertheless, despite the strong
evidence that insulin stimulates healing and thereby
decreases the time of wound closure, the underlying
mechanisms of insulin-induced improved healing are far
from understood.
Here we show that local application of insulin to excision
wounds stimulates keratinocyte migration and differenti-
ation, and that this is dependent on activation of the
PI3K-Akt pathway, followed by activation of Rac1, and
that the integrin α3 and the ECM molecule laminin 332
(LN332), are critical. We also show that insulin stimulates
a regenerative process in the wound tissue. Therefore,
insulin may prove to be useful in the treatment of chronic
wounds, dental/gum healing problems, and burns. These
are important findings because issues of impaired healing
and of lack of tissue regeneration have implications for
numerous health- and financially-related problems in this
country and elsewhere. The understanding of key ele-
ments of the signaling pathways induced by insulin dur-
ing stimulation of healing can lead to the development of
analogs that will function strictly in the healing process.
Results
Topical application of insulin accelerates and improves 
the quality of healing
To study the effects of insulin on wound healing, 7 mm
diameter excision wounds were performed on the back of
C57BL/6J mice, and locally treated with 0.03 U of insulin.
This dose of insulin was chosen because it significantly
stimulated healing (Fig. 1A) without affecting blood glu-
cose levels (unpublished data). We analyzed the wound
area throughout the healing process to monitor the time-
dependent effects of insulin on healing, and found that in
wounds treated with insulin the wound area was signifi-
cantly decreased at several time points (Fig. 1B), as was
the time to closure (control 10.25 ± 1.26 d, insulin 8.9 ±
0.32 d, P < 0.01). We found that insulin significantly
decreased wound area by day 3 after injury. In order to
elucidate the effects of insulin during this early stage of
healing, we took skin samples from control and insulin-
treated wounds, and compared the histological character-
istics of these two wounds. At day 3, we found that in
insulin-treated wounds the keratinocyte tongue was much
longer than that in the control wounds, suggesting that
insulin stimulates keratinocyte migration (Fig. 1C). When
we measured the extent of migration of the keratinocytes
by determining the length of migration of the tongue
from the margin of the wound to the tip of the migrating
keratinocytes, we found that there was a significant
increase in migration distance of the keratinocytes in insu-
lin-treated wounds (Fig. 1D). Furthermore, we also found
that following wound closure, the epidermis of insulin-
treated wounds is better defined and is characterized by an
increased number of epidermal reticular ridges and der-
mal papilla that are not evident in the control (Fig. 1E).
Insulin stimulates keratinocyte migration in a time- and 
dose-dependent manner
Histological observation of wounds treated with insulin
suggests that this protein stimulates keratinocyte migra-
tion. Although the effects of insulin on keratinocyte pro-
liferation are well established [20], its effect on migration
of these cells is not clear. To study the latter process, we
used HaCaT keratinocytes in culture. Cells were plated in
cloning rings and allowed to attach; the rings were
removed after marking their positions and the cells were
then treated with insulin. Migration distances from the
initial edge of the cells to the new edge of the cells were
measured at 24, 48, and 72 hr. At each time point, kerati-
nocytes treated with insulin showed increased migration
over the control (Fig. 2A, B). To determine whether this
effect is dose-dependent, we performed the migration
assays with different doses of insulin. A concentration as
low as 10-8 M insulin was able to increase keratinocyte
migration, which was highly significant after 48 hr of
treatment. However, concentrations ranging from 10-7 M
to 10-5 M significantly enhanced keratinocyte migration
by 24 h (Fig. 2C). To eliminate the possibility that this
migration is dependent on proliferation, we treated the
cells with mitomycin C, a potent DNA crosslinker and
hence inhibitor of cell proliferation, in the presence or
absence of insulin. Cells were pre-treated with 5 μg/ml of
mitomycin C for 3 hrs and then exposed to 10-7 M insulin
for 24 and 48 hrs. Although we observed that prolifera-
tion was halted, insulin-induced migration was not (Fig.Page 2 of 15
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Insulin accelerates wound healing and improves the quality of re-epithelializationFigure 1
Insulin accelerates wound healing and improves the quality of re-epithelialization. Excision wounds were per-
formed in C57BL/6J mice, and the healing process was monitored at different time points. (A) Representative images of 
wounds which were treated with vehicle (30 μl saline solution) or 0.03 u insulin/30 μl saline solution every two days. (B) 
Wound area was quantified every two days and expressed as the percentage of the original wound area (n = 9; Statistics are 
shown as comparisons between the treatment and control. *P < 0.05). Insulin significantly decreased wound area. (C, D) The 
length of the migrating tongues was determined by measuring the distance from the margin of the wound to the tip of the 
migrating keratinocytes at 40× magnification, in which one unit equals 25 μm. (C) Representative hematoxylin and eosin-
stained sections showing longer migrating tongue in insulin treated wounds. Scale bars indicate 50 μm. (D) Data are shown as 
the mean value +/- SD. Statistics are shown as comparisons between the treatment and control (n = 9). *P < 0.05. (E) Repre-
sentative hematoxylin and eosin-stained sections showing increased number of epidermal reticular ridges and dermal papilla in 
insulin treated healed wounds.
BMC Cell Biology 2009, 10:1 http://www.biomedcentral.com/1471-2121/10/12D), strongly suggesting that the two processes are inde-
pendently regulated by this hormone.
Insulin stimulates keratinocyte migration in an insulin 
receptor-dependent manner but in an EGF-independent 
manner
It has been shown that insulin activates both its own
receptor and the IGF-1 receptor, albeit with different affin-
ities [21]. These transmembrane proteins are both tyro-
sine kinases, share 60% homology, and activate a number
of insulin receptor substrates which then initiate signals
that lead to gene expression. These genes are involved in
many of the different effects of insulin on cells and ECM
molecules, as well as their receptors such as integrins,
which provide critical signals to guide cell movement. To
determine whether insulin-induced keratinocyte migra-
tion is dependent on one or both receptors, each group of
cells was pre-treated with either the neutralizing insulin
receptor Ab, 29B4, or the IGF-1 receptor tyrosine kinase
inhibitor, picropodophyllin and then treated with 10-7 M
or 10-6 M insulin. Pre-treatment of keratinocytes with the
insulin receptor Ab followed by 10-7 M insulin treatment
completely abolished insulin-induced migration, suggest-
ing that at this concentration these effects are primarily
mediated by the insulin receptor itself (Fig. 3A). When
cells were treated with the insulin receptor Ab and 10-6 M
insulin, the Ab only partially blocked insulin-induced
migration (Fig. 3A), suggesting that this concentration of
insulin may induce migration through both the insulin
and IGF receptors. To confirm these results, we pre-incu-
bated the cells with picropodophyllin for 1 hr and then
treated them with insulin. At 10-7 M, insulin-induced
keratinocyte migration was not affected, but the inhibitor
did decrease cell migration induced by 10-6 M insulin (Fig.
3B). Moreover, the keratinocyte migration resulting from
10-6 M insulin was abrogated when inhibiting both insu-
lin and IGF receptors using the 29B4 Ab and picropodo-
phyllin (Fig. 3B). Taken together, these data show that the
effect of high concentration (10-6 M) of insulin on kerati-
nocyte migration is mediated by both insulin and IGF-1
receptors, whereas the effect of lower concentrations of
insulin (10-7 M) is primarily mediated by the insulin
receptor. To study the effects of insulin that are mediated
only through the insulin receptor and its associated down-
stream signaling pathways, 10-7 M insulin was chosen for
the subsequent studies except when otherwise indicated.
Our previous studies showed that insulin stimulates EGF
expression in wound marginal keratinocytes of deep par-
tial thickness scald wounds in rats [16]. In order to
exclude the potential autocrine effects of EGF secretion on
insulin-induced keratinocyte migration, we treated the
keratinocytes with AG1478, a selective inhibitor of EGF-R
kinase, prior to treatment with insulin and measured
migration distances at 24 and 48 h. This EGF-R inhibitor
Insulin stimulation of keratinocyte migration is time- and dose-dependentFigure 2
Insulin stimulation of keratinocyte migration is time- 
and dose-dependent. Cells were assayed for migration 
using the cloning ring migration assay. (A, B) Cells were 
treated with 10-6 M insulin at multiple time points, as indi-
cated. Insulin significantly increased keratinocyte migration. 
(C) Cells were then treated with 10-8 M, 10-7 M, 10-6 M or 
10-5 M insulin, and migration distance measured 24 and 48 h 
after insulin treatment. The effect of insulin on keratinocyte 
migration was dose-dependent. (D) Cells were pre-treated 
with 5 μg/ml mitomycin C for 3 h followed by 10-7 M insulin, 
and migration distance measured 24 and 48 h after insulin 
treatment. The effect of insulin on keratinocyte migration 
was not abolished by mitomycin C. Each treatment group 
was performed in triplicate. Data are shown as the mean 
value +/- SD. Statistics are shown as comparisons between 
the treatment and control. *P < 0.05, **P < 0.01. ***P < 
0.001.Page 4 of 15
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migration (Fig. 3C), suggesting that this process does not
require EGF or its receptor.
PI-3K and Akt mediate insulin-induced keratinocyte 
migration
In order to determine the signal transduction pathways in
insulin-induced keratinocyte migration, we examined Akt
phosphorylation/activation by immunoblot analysis
[22,23], and found that the levels of phosphorylation of
this signal transduction mediator increased after 5 min of
insulin treatment, and remained elevated for at least 60
min (Fig. 4A). This effect was also dose-dependent (Fig.
4B). To determine whether Akt phosphorylation/activa-
tion was involved in insulin-induced keratinocyte migra-
tion, we infected keratinocytes with recombinant
adenovirus expressing the constitutively active mutant of
Akt (Akt-CA) or the dominant-negative mutant of Akt
(Akt-DN). Higher levels of p-Akt were found in the kerat-
inocytes expressing Akt-CA even without insulin treat-
ment when compared to cells expressing the Akt-DN (Fig.
4C). To determine whether Akt phosphorylation is impor-
tant in keratinocyte migration, we used the scratch wound
migration assay. This assay was used to avoid trypsinizing
and re-plating the cells because the viral infected cells
have decreased survival. We compared keratinocyte
migration distances with or without insulin treatment, in
cells expressing the Akt mutants (Fig. 4D, E). Uninfected
cells and cells infected with the null vector and then
treated with insulin as well as cells infected with the Akt-
CA, with or without insulin treatment, displayed the long-
est migration distance. In contrast, cells infected with Akt-
DN exhibited a significant decrease in migration, even
with insulin treatment, compared with all other groups,
illustrating the requirement of Akt for insulin-induced
keratinocyte migration.
PI3K is often involved in AKT phosphorylation. Therefore,
to determine whether insulin stimulation of keratinocyte
migration is dependent on PI3K activity, we performed
the migration assays in the presence of LY294002, an
inhibitor of PI3K. This treatment completely blocked
keratinocyte migration stimulated by insulin (Fig. 4F),
showing the importance of PI3K in this process. The dose
of LY294002 we used does not inhibit S6 kinase, which is
the effector of mTOR, nor does it affect MAP kinase, PKC,
or PI4K [24].
Insulin stimulates translocation of Rac1, but not RhoA, to 
the plasma membrane; this process requires PI3K-Akt 
activation and is involved in insulin-induced keratinocyte 
migration and wound healing
Small GTPases of the RhoA family play important roles in
cell motility. Therefore, we tested the possibility that the
PI3K-Akt pathway stimulates RhoA activation during
Insulin-induced keratinocyte migration is insulin receptor-depe dent an EGFR-independentFigure 3
Insulin-induced keratinocyte migration is insulin 
receptor-dependent and EGFR-independent. HaCaT 
Cells were plated in the cloning ring migration assay as 
described. (A) Cells were pre-treated with 1.5 μg of neutral-
izing insulin receptor Ab 29B4 for 1 h, then treated with 10-7 
M or 10-6 M insulin for 24 h. Neutralizing insulin receptor Ab 
inhibited 10-7 M but not 10-6 M insulin-induced cell migration, 
showing that the effect of 10-7 M insulin on keratinocytes is 
mediated primarily through the insulin receptor. (B) Cells 
were pre-treated with either 50 nM IGF-1 receptor inhibitor 
picropodophyllin, 1.5 μg neutralizing insulin receptor Ab 
29B4, or insulin receptor Ab 29B4 plus picropodophyllin for 
1 h, then treated with 10-7 M or 10-6 M insulin or left 
untreated for 24 h. The effects of a higher dose of insulin but 
not a lower dose are mediated by both the insulin receptor 
and the IGF-1 receptor. (C) Cells were pre-treated with 3 
μM of the EGF-R inhibitor AG1478 for 1 h, followed by 
treatment with 10-7 M insulin; migration distance was meas-
ured at 24 and 48 h after treatment. Insulin-induced migra-
tion was not prevented by the EGF-R inhibitor. Each 
treatment group was performed in triplicate. Data is shown 
as the mean value +/- SD. Statistics are shown as compari-
sons between the treatment and control, unless otherwise 
indicated. *P < 0.05, **P < 0.01. ***P < 0.001.Page 5 of 15
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PI-3K and Akt mediate insulin-induced keratinocyte migrationFigure 4
PI-3K and Akt mediate insulin-induced keratinocyte migration. (A) HaCaT cells were either left untreated or treated 
with 10-7 M insulin for the indicated time points, followed by immunoblot analysis of the cell lysates using an Ab that specifically 
recognizes phosphorylated Akt at Ser 473. This blot was reprobed with an Ab to Akt to ensure equal loading. Insulin increased 
Akt phosphorylation over time, with peak phosphorylation seen at 5 min. (B) HaCaT cells were either left untreated or 
treated with 10-8 M to10-5 M insulin for 5 min, and then analyzed as in (A). Insulin stimulated phosphorylation of Akt in a dose-
dependent manner. (C) HaCaT cells grown to 60–70% confluence were infected with adenovirus expressing constitutively 
active Akt (Akt-CA), dominant-negative Akt (Akt-DN) or the null adenovirus (Null) by incubating cells with the adenovirus for 
5 h. Forty-eight hours after infection, cells were treated with 10-7 M insulin for 3 min or left untreated. Phosphorylation of Akt 
and total Akt were detected by immunoblot. The Akt-DN inhibited insulin-induced Akt phosphorylation. (D, E) HaCaT Cells 
grown to 50–60% confluence were infected with adenovirus expressing Akt-CA, Akt-DN, or null adenovirus, as mentioned 
above. Forty-eight hours after infection, scratch wounds were made, and cells were treated with10-7 M insulin; migration dis-
tances were measured after 24 h of treatment. Again expression of the Akt-DN inhibited insulin-induced migration. (F) HaCaT 
cells were incubated with 50 μM of the PI3K inhibitor LY294002, 10-7 M insulin, or LY294002 for 1 h, followed by treatment 
with 10-7 M insulin. The migration distances were measured 24 h after treatment. Insulin induced keratinocyte migration was 
abolished by pre-treatment with the PI3K inhibitor LY294002. Results are representative of at least three independent experi-
ments. *P < 0.05 vs control; ***P < 0.001 vs control.
BMC Cell Biology 2009, 10:1 http://www.biomedcentral.com/1471-2121/10/1insulin-induced keratinocyte migration. Using immu-
nolabeling, we show that there was no significant differ-
ence in RhoA distribution shortly after insulin treatment
(Fig. 5A–C) nor did a change occur at least for 4 h. How-
ever, 3 min after insulin treatment, Rac1, another member
of the RhoA family of GTPases, translocated from the
cytosol to the plasma membrane, indicating its activation
(Fig. 5E). This redistribution effect was also seen after 5
min of insulin treatment (Fig. 5F). In addition, plasma
membrane ruffling was observed at the leading edge of
migrating keratinocytes, with Rac-1 being present in the
membrane of ruffles (Fig. 5F; arrow). To determine
whether this translocation is consistent with the activa-
tion of Rac1, we performed Rac1 pull down assays, which
can specifically pull down the active form of Rac, and
found elevated levels of active Rac1 after insulin treatment
(Fig. 5G). In order to confirm that Rac1 activation is
important in insulin-induced keratinocyte migration, we
transfected keratinocytes with plasmids containing
mutant forms of Rac1, and then observed the effects of
these mutants on insulin-stimulated cell migration. Kerat-
inocytes were transfected with either the constitutively
active form of Rac1 (V12, Rac1-CA), dominant-negative
mutant Rac1 (N17, Rac1-DN), or wild type Rac1 (Rac1-
WT). 24 h after transfection, scratch wounds were made in
the cell cultures, and cell migration distances were meas-
ured in non-transfected and transfected cells. After treat-
ment for 24 h, insulin stimulated migration in non-
transfected cells, as well as in cells transfected with Rac1-
CA or Rac1-WT. Cells transfected with Rac1-CA showed
increased migration, even without insulin treatment.
However, insulin-induced migration was eliminated in
cells transfected with Rac1-DN (Fig. 5H). To determine
whether the PI3K-Akt pathway is required for insulin-
induced Rac1 activation/translocation, LY294002 was
used to pre-treat the cells before insulin treatment. Insu-
lin-induced Rac1 activation (Fig. 5I) and translocation
(Fig. 5J) was inhibited by this PI3K inhibitor.
Insulin stimulates integrin a3 and LN332 production, which 
contributes to insulin-induced keratinocyte migration and 
wound healing
It is well known that the Rac1 GTPase is critical in
cytoskeleton re-organization, that the cytoskeleton inter-
acts with integrins on the cell surface, and that these
integrins interact with ECM molecules. It is also known
that the integrin α3β1 and LN332, a basement membrane
(BM) component, are important in both keratinocyte
migration and BM development. Therefore, we investi-
gated the possibility that insulin modulates LN332 and
integrin α3β1 expression in vitro and in vivo, and that these
proteins are involved in insulin-induced wound healing.
Keratinocytes were seeded in cloning rings in order to
observe the integrin α3 and LN332 at the migration edge.
Immunolabeling for integrin α3 showed higher levels of
this protein on the cell membrane after insulin treatment
(Fig. 6A, B). The increased integrin α3 levels were con-
firmed by immunoblot analysis (Fig. 6C).
Using similar methodology, LN332 was also found to be
elevated after insulin treatment, particularly at the migrat-
ing edge, with deposition of LN332 along the cell mem-
brane in some cells (Fig. 6D, E and inserts). Immunoblot
analysis showed an increase in the LN332 protein after
insulin treatment (Fig. 6F). To determine whether these
observations translate into changes in the migratory
behavior of keratinocytes, we observed the effect of func-
tion-inhibiting Abs to integrin α3 and LN332 on insulin-
induced keratinocyte migration (Fig. 6G). Cell migration
was inhibited when integrin α3 or LN332 were blocked
with these Abs, while basal migration remained virtually
unaffected. The effects of these blocking antibodies were
more obvious after 48 h of insulin treatment; at this time
point, functional blocking of α3 and LN332 affected both
basal and insulin-induced keratinocyte migration. Moreo-
ver, additional inhibition was observed when insulin
treatment was accompanied by treatment with both
integrin α3 and LN332 function-inhibiting Abs (Fig. 6G).
These results suggest that in vivo both α3 and LN332 are
involved in insulin-induced acceleration of wound clo-
sure. To test this possibility, we applied the function-
blocking Abs against both proteins to mouse excision
wounds, and found that inhibition of LN332 (Fig. 7A, B)
or integrin α3 (Fig. 7C, D) resulted in delays in healing,
primarily at early times after wounding. Histological
examination shortly after wound closure showed that
both inhibition of LN332 or integrin α3 resulted in a less
mature epidermis (Fig. 8A). When the antibodies to these
two molecules were applied, no reticular ridges were seen,
the basal cells were not well defined, the interactions of
the epidermis with the dermis were less well defined, and
appendages were not seen. Furthermore, staining for Col-
lagen IV (Fig. 8B), a component of basement membrane,
showed that in the wounds treated with the function-
inhibiting Abs for LN332, the basement membrane was
not well developed, and when treated with α3 integrin,
the basement membrane was irregular containing many
dense areas of Collagen IV deposition (compare with the
staining for wounds treated with insulin alone). When we
stained for keratin 10 (Fig. 8C), a marker of keratinocyte
differentiation [25], the basal keratinocytes of the wounds
treated with the inhibiting antibodies did not express ker-
atin 10. These results suggest that insulin promotes epi-
thelial basement membrane deposition and keratinocyte
differentiation.
Discussion
Previous work has shown that insulin improves wound
healing, but the mechanisms of its action on healing havePage 7 of 15
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Insulin stimulates Rac1 activation through PI3K-Akt in insulin-induced keratinocyte migrationFigure 5
Insulin stimulates Rac1 activation through PI3K-Akt in insulin-induced keratinocyte migration. (A-H). Cells 
were seeded in 8 well chamber slides for at least 24 h before the various treatments and then fixed and stained for either 
RhoA or Rac1 to visualize these molecules in the cell. (A-F) Cultures were either left untreated or treated with 10-7 M insulin 
for 3 or 5 min. (A-C) Staining for RhoA: (A), control, (B), insulin treatment 3 min (C), insulin treatment 5 min. Insulin does 
not stimulate translocation of RhoA to the cell membrane. (D-F) Staining for Rac1: (D), control. (E, F), insulin treatment at 3 
and 5 min. Arrowhead shows membrane ruffles. Insulin induces Rac1 membrane translocation as well as membrane ruffling in 
migrating cells. (G) Cells were treated with insulin for 5 min and a Rac1 pull-down assay performed. Insulin induced Rac1 acti-
vation. (H) Cells were transfected using lipofectin with plasmids expressing the constitutively active form of Rac1 (V12, Rac1-
CA), the dominant-negative mutant of Rac1 (N17, Rac1-DN) and the wild type Rac1 (Rac1-WT). Forty-eight hours after trans-
fection, scratch wounds were made, and cells were treated with 10-7 M insulin. Cell migration was monitored for 24 h after 
insulin. Insulin-induced keratinocyte migration was eliminated by Rac1-DN. Each treatment group was performed in triplicate. 
Data is shown as the mean value +/- SD. ***P < 0.001 vs control treatment. (I, J) Cells were pre-treated with 50 μM LY294002 
for 1 h followed by 10-7 M insulin treatment for 5 min. (I) Rac1 pull-down assay was then performed as mentioned above. 
Results are representative of three independent experiments. Levels of the active form of Rac1 were quantified by determining 
the ratio of the integrated density of the GTP binding form of Rac1 to GAPDH, the loading control, using ImageJ software. 
Data are shown as the mean value +/- SD. *P < 0.05 vs control treatment. Both Rac1 activation (I) and translocation to the 
plasma membrane (J) were inhibited by LY294002 pre-treatment.
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Insulin-induced integrin α3 and LN332 production contributes to keratinocyte migrationFigure 6
Insulin-induced integrin α3 and LN332 production contributes to keratinocyte migration. (A, B) Cells seeded in 
chamber slides were either left untreated or treated with 10-7 M insulin for 24 h, followed by immunolabeling with the anti-
integrin α3 Ab and FITC-conjugated secondary Ab. (A), control (B), insulin treatment 24 h. (C) Non-reducing western blot 
analysis of integrin α3 expression shows stimulation of this integrin by insulin in keratinocytes. Results are representative of 
three independent experiments. Levels of integrin α3 were quantified by determining the ratio of the integrated density of 
integrin α3 to GAPDH loading control using ImageJ software. Data are shown as the mean value +/- SD. *P < 0.05, **P < 0.01 
vs control treatment. (D, E) Cells seeded in chamber slides were either left untreated (D), or treated with 10-7 M insulin for 
24 h (E), followed by immunolabeling with the anti-LN332 Ab. Small boxes show higher magnification for more detailed distri-
bution of the staining. (F) Non-reducing immunoblot analysis of LN332 levels. Insulin stimulates secretion of LN332 by kerati-
nocytes. Results are representative of three independent experiments. Levels of LN332 were quantified by determining the 
ratio of the integrated density LN332 to GAPDH loading control using ImageJ software. Data are shown as the mean value +/- 
SD. *P < 0.05 vs control treatment. (G) Cells were wounded by scratching and then pre-treated with 25 μg/ml of function-
inhibiting Abs directed against LN332 (P3H9-2) and/or integrin α3 (P1B5) for 1 h, then treated with 10-7 M insulin. Migration 
distances were measured after 24 and 48 h of treatment. *P < 0.05 vs control or as indicated. Insulin induced keratinocyte 
migration was eliminated by both integrin α3 and LN332 function-inhibiting Abs. ***P < 0.001 vs control or as indicated. Each 
treatment group was performed in triplicate.
BMC Cell Biology 2009, 10:1 http://www.biomedcentral.com/1471-2121/10/1not been delineated. We used a variety of cell and molec-
ular approaches to determine the effects of insulin on
cutaneous wounds and have shown that insulin: (1) stim-
ulates keratinocyte migration in a dose- and time-depend-
ent manner; (2) acts in an insulin-receptor-dependent but
EGF/EGF-R-independent manner; (3) stimulates kerati-
nocyte migration through the PI3K-Akt-Rac1 pathway; (4)
stimulates keratinocytes to produce integrin α3 and
LN332, and cell migration in vitro and in vivo is dependent
on these molecules. The ability of this hormone to stimu-
late a variety of cell functions important for wound heal-
ing in an insulin-receptor-dependent manner creates the
ability to target processes that are dependent only on insu-
lin. Conversely, the ability to stimulate both the insulin
and IGF-1 receptors may broaden the applicability of
insulin in different wound conditions, particularly when
one receptor may be missing or dysfunctional (e.g. type II
diabetes).
Understanding the processes by which insulin accelerates
wound closure is important because it will provide insight
into potential manipulation of the healing process using
this hormone as well as the signaling molecules it acti-
vates. The results presented here show that stimulation of
keratinocyte migration by insulin involves the PI3K-Akt
pathway, and identifies Rac1, a small GTPase, as a mole-
cule activated downstream of PI3K-Akt. Support for these
conclusions includes the fact that these molecules are acti-
Integrin α3 and LN332 contribute to insulin-induced accelerating healingFigu e 7
Integrin α3 and LN332 contribute to insulin-induced accelerating healing. (A) Representative images of excision 
wounds performed as in Figure 1. After wounding, some wounds were treated with 5 μl LN332 Ab (P3H9-2, 1 mg/ml) for 5 
min, followed by 0.03 U insulin/30 μl PBS; other wounds were treated with 0.03 U insulin alone. Treatment was administered 
every two days until all wounds were closed. (B) Wound areas were quantified every two days and expressed as percentage of 
the area of the control (n = 3). Statistics are shown as comparisons between the LN332 Ab + insulin and insulin treatment. *P 
< 0.05. (C) Excision wounds were performed as above, except that wounds were treated with 5 μl of the anti-integrin α3 Ab 
(P1B5, 1 mg/ml) rather than the LN332 Ab. Function-inhibiting anti-integrin α3 Ab inhibited insulin-induced wound healing at 
early stages. (D) Wound areas were quantified as in (B). Statistics are shown as comparisons between the anti-integrin α3 Ab 
+ insulin and insulin treatment. *P < 0.05. (n = 3).Page 10 of 15
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LN332 and Integrin α3 inhibition decrease matrix and keratin 10 productionFigure 8
LN332 and Integrin α3 inhibition decrease matrix and keratin 10 production. Wound tissues were collected at 
wound closure and sections made. (A) Representative hematoxylin and eosin-stained sections show that in the LN332 and 
integrin α3 antibody-treated mice the epidermis is morphologically less differentiated, the basal keratinocytes are not well 
aligned, the reticular ridges not well formed, and the number of layers of keratinocytes is higher. (B) Immunolabeling for Col-
lagen IV, a marker for basement membrane development, shows that the LN332 antibody causes a dramatic decrease in base-
ment membrane deposition and integrin α3 antibody results in a basement membrane that contains many densities that 
contributes to irregularity of Collagen IV deposition. Solid lines demark the apical surface of the epidermis and arrowheads 
point to basement membrane). (C) Immunolabeling for keratin 10, a marker for keratinocyte differentiation, shows that the 
basal layers of the epidermis are disorganized and undifferentiated when LN332 and integrin α3 antibodies are applied to the 
wounds. Dashed lines delineate the basal surface of the epidermis and the vertical lines delineate the thickness of the epider-
mis.
BMC Cell Biology 2009, 10:1 http://www.biomedcentral.com/1471-2121/10/1vated upon insulin stimulation, and inhibition of each
molecule with specific inhibitors or dominant negative
proteins prevents insulin-induced keratinocyte migration.
Rac1 is known to regulate actin assembly [26] and to stim-
ulate formation of lamellipodia [27], thereby promoting
cell movement in response to external signals from
cytokines, growth factors and/or the ECM. Our results
support insulin-induced Rac1 activation in keratinocytes,
as shown by Rac1 translocation from the cytosol to the
cell membrane, the formation of membrane ruffles upon
insulin stimulation, and the increased levels of active Rac1
identified by the pull down assay. Moreover, we show that
Rac1 activation is dependent on the PI3K-Akt signaling
pathway in keratinocyte migration. Two recent papers
showed a strong activation of the PI3K pathway in the
wound margin keratinocytes [28,29]. Furthermore, epi-
dermal growth factor (EGF) or heregulin (HRG) have
been found to stimulate keratinocyte migration through
PI3K/Akt signaling [30]. These results, coupled with our
findings presented here, show that insulin can replace
some well known growth factors in wound healing.
The effects of insulin on keratinocyte migration described
above, led us to hypothesize that insulin-accelerated
wound healing involves increased expression of the
integrin α3β1 in keratinocytes as well as an increase in the
levels of LN332. The latter protein is a matrix molecule
secreted by migrating keratinocytes at the leading edge
[31], where it mediates keratinocyte polarity and persist-
ent migration [32,33]. After wounding, quiescent epider-
mal keratinocytes are activated and express the integrins
α6β4 and α3β1, which mediate their migration on LN332
and facilitate the development of the BM [34]. Our results
show that insulin stimulates keratinocyte integrin α3
expression and LN332 deposition, and that inhibition of
these proteins in vitro or in vivo inhibits insulin-induced
keratinocyte migration and wound healing, strongly sug-
gesting an important role for these molecules in insulin
stimulation of healing. This is a particularly important
finding, as the relationship between LN332 and migration
has been controversial. Indeed, previous studies have
implicated LN332 in promoting and inhibiting cell migra-
tion [34-36]; our results support a role for LN332 in pro-
moting keratinocyte migration.
In addition to its effects on keratinocyte migration during
wound healing, insulin also promotes attachment of the
epidermis to the dermis, the appearance of a well-organ-
ized epidermis, increased numbers of skin appendages,
and more dermal papilla and epidermal reticular ridges.
We also found that inhibiting integrin α3 and LN332
resulted in lack of full epidermal differentiation (as
shown by disorganization of the epidermis) and
decreased formation of dermal papilla and epidermal
reticular ridges.
Our results suggest that the direct application of insulin to
chronic wounds may improve wound healing by compen-
sating for a deficiency of insulin and/or IGF-1 in the
injured area. Previous studies have shown that the IGF-1
level is decreased in both streptozotocin (STZ)-induced
diabetic and normal rat incision wounds [37], and we
have also detected a decrease in insulin levels in rat scald
wounds (unpublished data). This insulin and IGF-1 defi-
ciency in the wound, along with our data showing that
insulin can function through stimulation of both insulin
and IGF-1 receptors, suggests that direct application of
insulin to the wound area may improve healing through
activation of both receptors. Indeed, it has been shown
that topical application of insulin accelerates healing of
infected cutaneous ulcerations in diabetic mice [12],
showing that insulin is promising for treatment of these
types of wounds. However, it has also been shown that
leptin-deficient obese/obese (ob/ob) diabetic mice have
dysfunctional signaling during wound healing [38], sug-
gesting that in these mice mediating the effect of insulin
on wounds might be different from those in normal
wounds or wounds in diabetic people.
When compared with other growth factors used to pro-
mote wound repair, insulin treatment is likely to be much
less expensive, more readily available, and has already
been approved by the FDA for human use. Moreover, a
significant numbers of reports have described that treat-
ment with growth factors, including most of the growth
factors that have been used clinically, or increased expres-
sion of growth factor receptors, lead to carcinogenesis [39-
41]. In contrast, insulin is safe, as shown by its use for
nearly a hundred years, hence it is likely safer than growth
factor alternatives. When choosing a concentration of
insulin for possible wound therapy, it is important to
remember that, although the highest concentrations of
insulin resulted in the greatest keratinocyte migration,
such doses may alter blood glucose levels in vivo.
Conclusion
In conclusion, we have shown that insulin interacts with
its receptor and affects multiple aspects of keratinocyte
behavior, including stimulation of cell motility, increased
expression of the cell surface adhesion molecule integrin
α3 and enhanced secretion of the ECM molecule LN332.
Furthermore, these effects extend to the dermis where we
observe a higher degree of tissue restoration than seen in
the control. These results strongly suggest that insulin
improves wound healing through an integrated effect not
only on re-epithelialization but also on the underlying
granulation tissue. Therefore, insulin treatment may
prove to be a powerful therapy for the treatment ofPage 12 of 15
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has been used in humans for a century without serious
adverse consequences.
Methods
Reagents
The human keratinocyte cell line HaCaT was a gift from
DKFZ (German cancer research center). DMEM was pur-
chased from Mediatech and FBS from Atlanta Biologicals.
Anti-RhoA (sc-179) Abs was purchased from Santa Cruz
Biotechnology. Anti-phospho-Akt Ser (473), anti-insulin
receptor (29B4) Abs and the PI-3K inhibitors, LY294002
came from Cell Signaling. The TRITC-anti-mouse Rac1 Ab
was purchased from Becton Dickinson and Company.
And the anti-human LN332 (P3H9-2) and anti-human
integrin α3 (P1B5) Abs were purchased from Chemicon.
The anti-mouse cytokeratin 10 Ab and rabbit polyclonal
to type collagen IV Ab were from Abcam. Anti-GAPDH Ab
was obtained from RDI Research Diagnostics. Recom-
binant human insulin and mitomycin C were purchased
from Sigma. Humulin Ultralene human insulin (rDNA
origin) extended zinc suspension was purchased from Eli
Lilly and Company. EGF-R inhibitor AG1478 and IGF-1
receptor tyrosine kinase inhibitor, Picropodophyllin were
purchased from Calbiochem. FITC-conjugated goat anti-
mouse immunoglobulin came from DAKO, and anti-
mouse Texas Red Ab from Amersham.
In vivo wound model
C57BL/6J mice were purchased from The Jackson Labora-
tory (USA), and housed at the University of California,
Riverside (UCR) vivarium. All experimental protocols
were approved by the UCR Institutional Animal Care and
Use Committee. Experiments were performed using 8–12
wk old mice. Mice were anesthetized with a single intra-
peritoneal injection of ketamine (80 mg/kg body weight)/
xylazine (16 mg/kg body weight). Full-thickness 7 mm
punch wounds (excision of the skin and the underlying
panniculus carnosus) were made on the back of the mice.
The wounds were then treated as indicated for the various
experiments and covered with a transparent dressing (Bio-
clusive, Johnson & Johnson Medical Limited, USA) until
day 3 after wounding. After this time, the dressings were
removed, and the wounds were exposed. Healing was
monitored by taking photographs at the indicated time
points. In addition, the wound area was drawn on a trans-
parent plastic film for further comparisons of wound area
at each time point. For graphing purposes, wound closure
was expressed as percentage of wound area (area of
wound measured at any one day post wounding divided
by the initial wound area).
Histology
At day 3 after wounding, as well as the day that complete
healing occurred, animals were anesthetized, and skin
samples consisting of the wounded area plus 5 mm of the
surrounding unwounded and/or healed skin area were
collected. Tissues were fixed in 4% pareformaldehyde for
2 h and incubated in 0.1 M glycine/PBS for 1 h followed
by 15% and 30% sucrose before embedding in OCT (Tis-
sue-Tek, Sakura Finetek. USA, Inc), freezing in a slush of
ethanol/dry ice, and stored in -80 C. After sample collec-
tion, the mice were euthanized using CO2. The extent of
migration of the keratinocyte was measured in sections
stained with Hematoxylin and Eosin. The length of migra-
tion tongue was determined by the distance from the mar-
gin of the wound to the tip of the migrating keratinocytes.
Cell Culture
The human keratinocyte cell line HaCaT was cultured in
5% CO2 at 37°C in DMEM supplemented with 10% FBS,
10 units/ml penicillin, and 10 μg/ml streptomycin sulfate
(GIBCO, Invitrogen Corporation).
Immunoblotting
Cells were treated as indicated, and then washed with ice-
cold 1 × PBS, and lysed on ice with lysis buffer containing
0.5% Triton X100, 0.5% Nonidet P-40, 10 mM Tris, pH
7.5, 2.5 mM KCl, 150 mM NaCl, 30 mM b-glycerophos-
phate, 50 mM NaF, 1 mM Na3VO4, 0.1% SDS and addi-
tional protease and phosphatase inhibitor cocktails
(Sigma). Protein concentrations were measured using the
DC protein assay kit (Bio-Rad). Equal amounts of protein
in the cell extracts were mixed with sample buffer, boiled,
and analyzed using 10% acrylamide SDS-PAGE. Immuno-
blotting was performed with the indicated primary Abs
and the appropriate HRP-conjugated secondary Abs, fol-
lowed by incubation with West Dura extended duration
substrate (Pierce Biotechnology). Blots were then re-
probed for house keeping proteins to show equal loading.
For LN332 and integrin α3, protein extracts were prepared
as indicated above, but were mixed with non-reducing
sample buffer, and, for LN332 detection, samples were
boiled. The extracts were then analyzed using 7.5% acry-
lamide SDS-PAGE, followed by immunoblotting as
described above.
In vitro Migration Assays
We used two types of assays: (i) The cloning ring assay in
which 2.0 × 104 HaCaT cells were plated in a cloning ring
6 mm diameter set within a 35-mm cell culture dish. Four
hours after seeding, the cylinder was removed, the cell
edges were marked, and migration was measured at the
indicated times by measuring the distance from the initial
cell edge to the edge of the migrating cells; (ii) For the
scratch assay the HaCaT cells were plated in cell culture
dishes and after reaching confluence, scratch wounds
were made as previously described [42]. Briefly, we used
the small end of a 1 ml pipet tip to scratch the cells on a
35 mm plate, and then marked the edges of the scratches.Page 13 of 15
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measuring the distance from the initial cell edge to the
edge of the migrating cells. The scratch assay was used
when we performed transfection experiments to avoid
trypsinization and re-plating into the cloning ring.
Transient Adenoviral Transfection
Recombinant adenovirus containing the constitutively
active mutant of Akt (Akt-CA), the dominant-negative
mutant of Akt (Akt-DN), and the parental adenoviral vec-
tor (referred to as null) were gifts from John Shyy (UCR,
Biomedical Sciences Division). Cells were infected with
various recombinant adenoviruses at 50 moi; media was
changed after 5 h of incubation with adenovirus. After 48
h of infection, cells were subjected to further treatment, as
indicated in the Results section. Plasmids expressing the
constitutively active form of Rac1 (V12, Rac1-CA), the
dominant-negative mutant Rac1 (N17, Rac1-DN) and the
wild type Rac1 (Rac1-WT; gifts from Dr. Miguel Del Pozo,
Centro National de Investigaciones Cardiovasculares,
Madrid, Spain) were transfected using Lipofectin (Invitro-
gen, USA) according to the manufacturer's protocol.
Briefly, one day before transfection, the cells were plated
in growth media without antibiotics. Transfections were
performed at 40–60% cell confluence. 2 μg of DNA in 100
μl of DMEM without serum, were mixed gently with 5 μl
Lipofectin in 100 μl of MDEM without serum. This mix-
ture was incubated for 15 min at room temperature and
then added to the cells which were then incubated at
37°C and 5% CO2 for 16 h. At this time the medium was
replaced with medium containing serum and analyzed at
the appropriate times.
Immunolabeling
Cells were cultured in chamber slides (Nunc), and fixed in
4% paraformaldehyde for 20 min, rinsed with PBS, incu-
bated in PBS containing 0.1 M glycine for 20 min, and
blocked with 3% BSA, 0.1%Triton X-100 in PBS for 30
min. Primary Abs in 1% BSA/PBS were applied to the sam-
ple for 2 h at room temperature, washed, and incubated
with 1:50 dilution of FITC or Texas red-conjugated sec-
ondary Abs for 1 h at room temperature. After washing,
the cells were mounted in Vectashield containing DAPI
(Vector Laboratories, Inc. Berlingame, CA). Immunofluo-
rescence was visualized and imaged using a Leica SP2 laser
scanning confocal microscope. For frozen tissues, 8-μm
cryosections were washed in 1 × PBS to remove the OCT,
fixed in 2% paraformaldehyde for 10 min, incubated in
0.1 M glycine in 1 × PBS, followed by the primary and sec-
ondary Abs using the same procedure as indicated above.
Statistical Analysis
Data are shown as mean × SD. Data analysis was per-
formed using the unpaired Student's t-test on raw data
using GraphPad Instat software (GraphPad Software Inc.).
Statistical comparison between more than two groups was
performed by One-way ANOVA.
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